Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China

Jiang, Yongpo; He, Susu; Zhang, Chao; Wang, Xiaodan; Chen, Xi; Jin, Yingying; He, Zebao; Cai, Minjie; Lin, Zongmei; Ying, Lingjun; Mou, Jianli; Zhao, Haihong; Lin, Ronghai; Zhang, Sheng; Wu, Xiaomai; Chen, Haixiao; Lv, Dongqing

Background: The number of patients with pneumonia stemming from the 2019 novel coronavirus (COVID-19) infection has increased rapidly However, the clinical characteristics of discharged patients remain little known Here, we attempt to describe the clinical characteristics and treatment experiences of discharged cases from Taizhou, China Methods: A total of 60 patients with COVID-19-infected pneumonia who were discharged from Taizhou Enze Medical Center (Group), from January 31, 2020, to February 16, 2020, were included in the analysis The discharge criteria were based on the New Coronavirus Pneumonia Prevention and Control Program (Fifth Edition, China) Results: Of the 60 patients, the median age was 41 years, and 58 3% were male Only 13 3% of patients were identified as having severe novel coronavirus pneumonia All patients received combined antiviral treatment on admission, including beta-interferon, lopinavir/tonavir, Abidol and oseltamivir All patients with severe conditions received gamma globulin and hormone therapy No patients had endotracheal intubation or died The median duration from symptom onset to hospitalization was 3 (range, 0-15) days The median duration of COVID-19 shedding was 14 (range, 5-26) days, and the median duration of hospital stay was 15 (range, 7-23) days Conclusions: Early therapy and comprehensive therapy are key to the outcome for patients with COVID-19-infected pneumonia, especially for those with severe pneumonia Trial registration number: ChiCTR2000029866